Seeking Alpha · 11 Aug 2026positive
Regenxbio reported a strong quarter with GAAP EPS of $0.43 and 407% year-over-year revenue growth, driven by milestone revenue. The company holds $313 million in pro forma cash and has multiple late-stage catalysts upcoming over the next 12–18 months, including RGX-202, pivotal wet AMD data, and a RGX-121 resubmission.
Why it matters — A RGNX watcher would care because the article highlights a strong quarter, an extended cash runway into late 2027, and a dense pipeline of late-stage catalysts that could drive significant developments for the company.
MarketBeat · 7 Aug 2026positive
REGENXBIO reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, including completed enrollment in its Duchenne muscular dystrophy confirmatory study, an agreed path to resubmit its Hunter syndrome therapy application, and the start of a pivotal diabetic retinopathy study under its AbbVie collaboration.
Why it matters — A RGNX watcher would care because these pipeline milestones mark concrete regulatory and clinical advancement across three key late-stage programs.
Seeking Alpha · 6 Aug 2026neutral
Seeking Alpha published the transcript of REGENXBIO Inc.'s Q2 2026 earnings call. The piece is the full transcript of the company's second-quarter 2026 earnings conference call.
Why it matters — RGNX watchers would care because the earnings call transcript provides direct insight into management's discussion of the company's quarterly results and outlook.
Zacks Investment Research · 6 Aug 2026positive
Regenxbio reported second-quarter earnings of $0.43 per share, surpassing the Zacks Consensus Estimate of $0.12 per share. This compares favorably to a loss of $1.38 per share in the same quarter a year ago.
Why it matters — The quarter marked a significant improvement from the prior-year loss and came in well ahead of analyst expectations, offering RGNX watchers a notable earnings milestone.
PRNewsWire · 6 Aug 2026positive
REGENXBIO reported Q2 2026 financial results and operational highlights. Key updates include a Q3 2026 BLA submission for RGX-202 in Duchenne muscular dystrophy with potential accelerated approval in 2H 2027, durable long-term surabgene lomparvovec (ABBV-RGX-314) data, topline data from the ATMOSPHERE and ASCENT wet AMD studies expected in Q4 2026, and a resubmission path for RGX-121 for Hunter syndrome following a productive July Type A meeting with the FDA. Over $200 million in new capital raised in July 2026 extends the cash runway into Q4 2027, with pro forma cash exceeding $310 million at the end of Q2 2026.
Why it matters — A RGNX watcher would care because the update maps out near-term regulatory and clinical catalysts, including the RGX-202 BLA and pivotal wet AMD topline data, alongside an extended cash runway into Q4 2027.
